Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
EQL Pharma AB ( (SE:EQL) ) has issued an announcement.
EQL Pharma AB reported a successful year-end with a 45% increase in sales and a 174% rise in operating profit, driven by the acquisition of new products and a significant distribution deal outside Europe. The company has surpassed its five-year growth targets and is poised for continued expansion with a new strategic plan aiming for a 30% sales growth in the coming year.
More about EQL Pharma AB
EQL Pharma AB operates in the pharmaceutical industry, focusing on the development and distribution of niche generic drugs. The company is expanding its market presence with a significant emphasis on non-European markets, as evidenced by its recent distribution agreement in the Gulf countries.
Average Trading Volume: 20,129
Current Market Cap: SEK2.3B
Find detailed analytics on EQL stock on TipRanks’ Stock Analysis page.